노스캐롤라이나의 버킷 림프종 임상 시험
버킷 림프종 관련 연구 13개가 노스캐롤라이나 내 여러 지역에서 참여자를 모집하고 있습니다.
노스캐롤라이나의 도시
공식 연구 텍스트(영어)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- 외 2개
피험자 모집 중2상
366 Days – 46 Years · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- East Carolina University, Greenville
- Wake Forest University Health Sciences, Winston-Salem
피험자 모집 중3상
18세 ~ 39세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Wake Forest University Health Sciences, Winston-Salem
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Duke University Medical Center, Durham
- 외 2개
피험자 모집 중2상
365 Days · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT07648264A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- 외 3개
피험자 모집 중2상
1세 ~ 30세 · 모든 성별 · 2026. 9. 1. 업데이트됨 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- 외 4개
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Levine Children's Hospital, Charlotte
피험자 모집 중2상
7세 ~ 25세 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
피험자 모집 중1/2상
13세 ~ 90세 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06533579Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- 외 4개
피험자 모집 중관찰 연구
65세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT01137825Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 13. 업데이트됨 · NCT05544019Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
피험자 모집 중관찰 연구
18세 ~ 120세 · 모든 성별 · 2025. 10. 27. 업데이트됨 · NCT01137643The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Atrium Health - Levine Cancer Center, Charlotte
피험자 모집 중2상
1세 ~ 25세 · 모든 성별 · 2025. 5. 4. 업데이트됨 · NCT03509961ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.